Stephen Fowler
Overview
Explore the profile of Stephen Fowler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
885
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tidmarsh B, Ludlow S, Fowler S
BMJ Case Rep
. 2025 Mar;
18(3).
PMID: 40055015
Inducible laryngeal obstruction (ILO) is an under-recognised cause of refractory breathlessness. It presents with an acute onset of difficulty in breathing and is often mistaken for respiratory conditions such as...
2.
Murray C, Fowler S, Drake S, Wang R, Durrington H, Wardman H, et al.
BMJ Open
. 2024 Oct;
14(10):e083908.
PMID: 39461867
Introduction: The diagnosis of asthma is often based on characteristic patterns of symptoms in the absence of an alternative explanation, resulting in over and under diagnosis. Therefore, diagnostic guidelines usually...
3.
King J, Dockry R, Marsden P, Fowler S, Smith J
Eur Respir J
. 2024 Sep;
64(4).
PMID: 39227071
No abstract available.
4.
Maltinsky W, Henton S, Spaltro G, Fowler S, Chaudhuri R, Higgs C, et al.
J Asthma
. 2024 Aug;
62(2):226-235.
PMID: 39212316
Background: People with dysfunctional breathing (DB) experience symptoms such as air hunger and breathing pattern irregularities. The condition is often comorbid with other respiratory conditions, as well as anxiety and...
5.
Park S, Fowler S, Shaw D, Adcock I, Sousa A, Djukanovic R, et al.
Allergy Asthma Immunol Res
. 2024 Aug;
16(4):338-352.
PMID: 39155735
Purpose: Asthma is a clinical syndrome with various underlying pathomechanisms and clinical phenotypes. Genetic, ethnic, and geographic factors may influence the differences in clinical presentation, severity, and prognosis. We compared...
6.
Ozbey A, Keemink J, Wagner B, Pugliano A, Krahenbuhl S, Annaert P, et al.
Drug Metab Dispos
. 2024 Apr;
52(7):614-625.
PMID: 38653501
Hepatic impairment, due to liver cirrhosis, decreases the activity of cytochrome P450 enzymes (CYPs). The use of physiologically based pharmacokinetic (PBPK) modeling to predict this effect for CYP substrates has...
7.
Djukanovic R, Brinkman P, Kolmert J, Gomez C, Schofield J, Brandsma J, et al.
Am J Respir Crit Care Med
. 2024 Apr;
210(3):288-297.
PMID: 38635834
The anti-IgE monoclonal antibody omalizumab is widely used for severe asthma. This study aimed to identify biomarkers that predict clinical improvement during 1 year of omalizumab treatment. One-year open-label Study...
8.
Spreafico A, Munoz Couselo E, Irmisch A, Bessa J, Au-Yeung G, Bechter O, et al.
Front Oncol
. 2024 Apr;
14:1346502.
PMID: 38577337
Introduction: Although checkpoint inhibitors (CPIs) have improved outcomes for patients with metastatic melanoma, those progressing on CPIs have limited therapeutic options. To address this unmet need and overcome CPI resistance...
9.
Milani N, Parrott N, Galetin A, Fowler S, Gertz M
CPT Pharmacometrics Syst Pharmacol
. 2024 Feb;
13(4):524-543.
PMID: 38356302
Organ-on-a-chip (OoC) systems are a promising new class of in vitro devices that can combine various tissues, cultured in different compartments, linked by media flow. The properties of these novel...
10.
Ozbey A, Fowler S, Leys K, Annaert P, Umehara K, Parrott N
Drug Metab Dispos
. 2023 Oct;
52(1).
PMID: 37879848
Physiologically-based pharmacokinetic (PBPK) modeling has become the established method for predicting human pharmacokinetics (PK) and drug-drug interactions (DDI). The number of drugs cleared by non-CYP enzyme metabolism has increased steadily...